Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05972135 · ClinicalTrials.gov registry record · Phase 2
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
A Phase 2 study of Multiple Myeloma, sponsored by SCRI Development Innovations.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 17
- Study locations
NCT05972135 is a Phase 2 study of Multiple Myeloma that is actively recruiting participants, run by SCRI Development Innovations. The registered enrollment target is 100 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The trial reports 17 study locations across 12 states.
The verdict
NCT05972135, a Phase 2 study of Multiple Myeloma, is actively recruiting participants, sponsored by SCRI Development Innovations.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Talquetamab
- DRUG Tocilizumab
- DRUG Oral Dexamethasone
Study Locations (17)
Texas
- Texas Oncology - Austin
- Texas Oncology - San Antonio - San Antonio
- Texas Oncology - Northeast Texas - Tyler
Colorado
- Colorado Blood Cancer Institute - Denver
- Rocky Mountain Cancer Center - Denver
Tennessee
- TriStar Bone Marrow Transplant - Nashville
- Vanderbilt- Ingram Cancer Center - Nashville
Virginia
- Virginia Cancer Specialists - Fairfax
- Blue Ridge Cancer Center - Roanoke
Arizona
- Arizona Oncology Associates - Tucson
Delaware
- Medical Oncology Hematology Consultants - Newark
Florida
- Florida Cancer Specialists - Lake Mary
Maryland
- Maryland Oncology Hematology - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-10-23 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05972135
The ClinicalTrials.gov registry entry for NCT05972135 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (82% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Teclistamab is the first listed.
NCT05972135 reports 17 study locations spanning 12 distinct geographic areas - top geographies include Texas, Colorado, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05972135 about?
NCT05972135 is a clinical study titled "Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma". This is a phase II study to evaluate the outpatient administration of Teclistamab or Talquetamab in Multiple Myeloma patients
What is the current status of trial NCT05972135?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-10-23. Estimated completion is 2027-10.
What conditions does trial NCT05972135 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT05972135?
The interventions under investigation include: Teclistamab (DRUG), Talquetamab (DRUG), Tocilizumab (DRUG), Oral Dexamethasone (DRUG).
Who is sponsoring clinical trial NCT05972135?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05972135 being conducted?
This trial has 17 study locations across Arizona, Colorado, Delaware, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.